Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Powell Industries (POWL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Powell Industries — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Powell Industries trades at $166.09 (market cap $6.66B). The key difference: Powell Industries is far larger — about 6.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Powell Industries pays a 0.2% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Powell Industries for 6 Days on average.
| MRVI | POWL | |
|---|---|---|
Market Cap | $972.90M | $6.66B |
Volume | 4,325,710 | 559,090 |
Sector | Health | Industrials |
52-Week High | $9.00 | $322.05 |
52-Week Low | $2.83 | $94.02 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $1.08B | $6.03B |
Dividend Yield | — | 0.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Powell Industries (POWL) trades at $182.79, down 1.4% with bearish technical signals. The company shows strong profitability with 16.49% net margin and 28.25% ROE, though recent quarters missed earnings estimates. Analyst consensus is mixed with 30% buy ratings but a $284 price target suggesting 55% upside. The stock faces near-term pressure from technical weakness despite solid fundamentals and a $2.4 billion backlog supporting future growth.
The investment case balances strong operational performance against technical headwinds. Upside potential exists from backlog conversion and capacity expansion, but risks include execution challenges and market volatility. With valuation metrics elevated (P/E 34.99), successful earnings delivery in upcoming quarters remains critical for sustaining investor confidence and achieving analyst targets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Powell Industries
Powell Industries designs and manufactures electrical equipment and engineered solutions for power distribution and control. Its products are used across energy, utility, industrial, and commercial infrastructure.
Read more on POWL →
